Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.

Gomez-Peralta F, Lecube A, Fernández-Mariño A, Alonso Troncoso I, Morales C, Morales-Pérez FM, Guler I, Cadarso-Suárez C

Diabetic medicine : a journal of the British Diabetic Association13 Jul 2018Cited by 11 (Europe PMC)

PMID29943854DOI10.1111/dme.13769PepBankPUB-29943854

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in a real-world setting, HbA1c decreased gradually during 24 months of liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, HbA1c levels linked to liraglutide treatment fell gradually over 24 months.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Upon liraglutide treatment, HbA_1c , body weight, mean systolic and diastolic blood pressure, and lipid levels decreased gradually.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385401
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in a real-world setting, body weight decreased gradually during 24 months of liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, body weight linked to liraglutide treatment fell gradually over 24 months.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Upon liraglutide treatment, HbA_1c , body weight, mean systolic and diastolic blood pressure, and lipid levels decreased gradually.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385402
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in a real-world setting, mean systolic blood pressure decreased gradually during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, systolic blood pressure linked to liraglutide treatment fell gradually.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Upon liraglutide treatment, HbA_1c , body weight, mean systolic and diastolic blood pressure, and lipid levels decreased gradually.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385403
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in a real-world setting, mean diastolic blood pressure decreased gradually during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, diastolic blood pressure linked to liraglutide treatment fell gradually.
Peptide
Liraglutide
Outcome
DecreaseDiastolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Upon liraglutide treatment, HbA_1c , body weight, mean systolic and diastolic blood pressure, and lipid levels decreased gradually.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385404
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in a real-world setting, lipid levels decreased gradually during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, blood fat levels linked to liraglutide treatment fell gradually.
Peptide
Liraglutide
Outcome
DecreaseLipid levels
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Upon liraglutide treatment, HbA_1c , body weight, mean systolic and diastolic blood pressure, and lipid levels decreased gradually.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385405
06HumanObservational studyOther
In adults with type 2 diabetes, longer treatment with liraglutide predicted a better HbA1c response.
In plain wordsIn adults with type 2 diabetes, longer liraglutide treatment was linked to a better HbA1c response.
Peptide
Liraglutide
Outcome
Not applicableTreatment duration as predictor of HbA1c response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
GAMMs demonstrated that longer treatment with liraglutide was a predictor of improved HbA_1c response
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385406
07HumanObservational studyOther
In adults with type 2 diabetes, higher baseline HbA1c predicted a worse HbA1c response to liraglutide.
In plain wordsIn adults with type 2 diabetes, a higher starting HbA1c was linked to a smaller HbA1c response to liraglutide.
Peptide
Liraglutide
Outcome
Not applicableBaseline HbA1c as predictor of HbA1c response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
whereas higher baseline HbA_1c , longer Type 2 diabetes duration and treatment with insulin were predictors of worse HbA_1c response
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385407
08HumanObservational studyOther
In adults with type 2 diabetes, longer diabetes duration predicted a worse HbA1c response to liraglutide.
In plain wordsIn adults with type 2 diabetes, longer diabetes history was linked to a smaller HbA1c response to liraglutide.
Peptide
Liraglutide
Outcome
Not applicableDiabetes duration as predictor of HbA1c response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
whereas higher baseline HbA_1c , longer Type 2 diabetes duration and treatment with insulin were predictors of worse HbA_1c response
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385408
09HumanObservational studyOther
In adults with type 2 diabetes, treatment with insulin predicted a worse HbA1c response to liraglutide.
In plain wordsIn adults with type 2 diabetes, also using insulin was linked to a smaller HbA1c response to liraglutide.
Peptide
Liraglutide
Outcome
Not applicableInsulin treatment as predictor of HbA1c response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
whereas higher baseline HbA_1c , longer Type 2 diabetes duration and treatment with insulin were predictors of worse HbA_1c response
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385409
10HumanObservational studyOther
In adults with type 2 diabetes, higher baseline weight predicted an improved weight response to liraglutide.
In plain wordsIn adults with type 2 diabetes, a higher starting weight was linked to a better weight response to liraglutide.
Peptide
Liraglutide
Outcome
Not applicableBaseline weight as predictor of weight response
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Higher baseline weight, longer treatment with liraglutide and the interaction between metformin and time were predictors of improved weight response.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385410
11HumanObservational studyOther
In adults with type 2 diabetes, longer treatment with liraglutide predicted an improved weight response.
In plain wordsIn adults with type 2 diabetes, longer liraglutide treatment was linked to a better weight response.
Peptide
Liraglutide
Outcome
Not applicableTreatment duration as predictor of weight response
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Higher baseline weight, longer treatment with liraglutide and the interaction between metformin and time were predictors of improved weight response.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385411
12HumanObservational studyOther
In adults with type 2 diabetes, the interaction between metformin and time predicted an improved weight response to liraglutide.
In plain wordsIn adults with type 2 diabetes, using metformin over time was linked to a better weight response to liraglutide.
Peptide
Liraglutide
Outcome
Not applicableMetformin-by-time interaction as predictor of weight response
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Higher baseline weight, longer treatment with liraglutide and the interaction between metformin and time were predictors of improved weight response.
1 context sentence(design, population, supporting numbers)
Summary · context
We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015.
Report a problemFND-2994385412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.